Valneva SE VALN
5.65 USD -0.01 (-0.18%)
Regular-session close
5.65 0.00 0.00%
After hours · Nov 16, 4:00 PM ET
5.59 Day range 5.81
4.75 52-week range 12.18
- YTD
- -35.94%
- 1 year
- -37.57%
News
benzinga.com Valneva Reports Five-Year Antibody Persistence for Chikungunya Vaccine Valneva SE (NASDAQ:VALN) reported positive five-year antibody persistence results for its single-dose chikungunya vaccine, IXCHIQ, confirming that the shot delivers lasting immune protection across…
benzinga.com Valneva Reports Five-Year Antibody Persistence for Chikungunya Vaccine Valneva reports 94% of adults sustained antibody protection five years after receiving its single-dose chikungunya shot IXCHIQ.benzinga.com Valneva Says Single-Dose Chikungunya Vaccine IXCHIQ Showed Antibody Persistence Consistent With Prior Results, In Line With Company Expectations, With 94% Seroresponse At Year 5 Across Age Groups 94% of participants maintained seroresponse five years after a single vaccinationComparable antibody persistence observed in older (65+) and younger adultsData further reinforce IXCHIQ®'s…
globenewswire.com Valneva Reports Sustained 94% Seroresponse Five Years After a Single Dose of Chikungunya Vaccine IXCHIQ® Lyon (France), November 10, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported positive five-year antibody persistence data for its single dose…
benzinga.com Valneva Evaluates Next Steps for Bacterial Infection Vaccine Following Successful Phase 2 Studies Valneva SE (NASDAQ:VALN) announced positive data from two Phase 2 clinical trials evaluating Shigella4V2 (S4V2), the world's most clinically advanced tetravalent bioconjugate candidate targeting…
